Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer.

ABSTRACT:

Background and objective

Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features.

Methods

We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected  NSCLC samples using PCR followed by direct sequencing.

Results

The present study included 53 (91.4%) men and 5 (8.6%) women, with a median age of 59 (ranging from 44 to 94 years old). EGFR mutations were detected in 23 patients, with an overall ra

SUBMITTER: Lahmadi M 

PROVIDER: S-EPMC8325123 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature